6M Group LLC published an article detailing the ESC readout showing Alnylam Pharmaceuticals next-gen silencers found daylight, with knockdown levels reaching 92%+ for Nucresiran.
Public source
Publisher name
Public post
Alnylam Pharmaceuticals next‑gen silencers are finding daylight. This ESC readout makes one thing clear: the silencer story is far from over. The data split between Astr…
Company
6M Group LLC
Simple. NOT EASY. Effective.
- Industry
- Business Consulting and Services
- Location
- Leominster, US
- Company size
- 2–10 employees
About 6M Group LLC
My Philosophy: Simple. NOT EASY. Effective. I help people and businesses cut the noise, focus on what matters, and execute with discipline. Clarity creates speed. Discipline creates results. Energy creates momentum. The right path is usually clear. The hard part is committing to it, showing up with energy, and holding the standard long enough to win. I operate with confidence in my process, intensity when it matters, and standards that elevate the people around me. I’ve spent years inside high‑pressure environments - sales, operations, leadership - and the pattern is always the same: People DON'T fail because they’re incapable. They fail because they’re overwhelmed, distracted, and lack clear direction. My work fixes that. I help teams: - Clarify their priorities - Move with urgency and confidence - Build simple, effective systems - Increase accountability - Improve hiring and talent decisions I bring an energetic, positive, no‑nonsense approach that gets people moving fast and staying focused. If you want to eliminate the noise and start winning with clarity and momentum, let’s connect.
See moreLatest activity
Latest activity from 6M Group LLC
30 signals
Sales & Marketing
6M Group LLC supported AstraZeneca's new #Breztri campaign, which leverages AI-generated animals to promote the triple therapy asthma maintenance inhaler, achieving $1.2B in annual sales and positioning the brand as modern, accessible, and patient-centered.
Presence & Recognition
6M Group LLC noted that Ionis Pharmaceuticals, Inc. has declared themselves a rare-disease powerhouse with the first-ever FDA-approved therapy for Alexander disease.
Capital & Finance
6M Group LLC reported that the U.K. biotech ecosystem saw the Best funding quarter in five years.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
NH Biotech Consulting
NH Biotech Consulting published research on mRNA-3705 in methylmalonic acidaemia, where modelling supported a 0.1 mg/kg starting dose and subsequent escalation identified clearer biomarker and clinical effects at higher doses.
Research & Knowledge
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. announced topline results from the Phase 3 Lp(a)HORIZON clinical trial in patients with cardiovascular disease and elevated levels of Lp(a) with partner Novartis.
Customers & Market
DeciBio
DeciBio notes that Full CARDIO-TTRansform data from Ionis Pharmaceuticals, Inc. and AstraZeneca, presented at ESC and published in NEJM, confirmed eplontersen missed its primary composite endpoint in ATTR-CM despite a 77% reduction in serum TTR.
Research & Knowledge
SNP Biopharma Consulting
SNP Biopharma Consulting presented Phase 3 results for plozasiran (REDEMPLO®), an siRNA targeting APOC3, at the ESC Congress 2026.
Presence & Recognition
Alnylam Pharmaceuticals